198 related articles for article (PubMed ID: 31714026)
1. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Stefka AT; Johnson D; Rosebeck S; Park JH; Nakamura Y; Jakubowiak AJ
Cancer Med; 2020 Jan; 9(1):324-334. PubMed ID: 31714026
[TBL] [Abstract][Full Text] [Related]
2. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Ikeda Y; Park JH; Miyamoto T; Takamatsu N; Kato T; Iwasa A; Okabe S; Imai Y; Fujiwara K; Nakamura Y; Hasegawa K
Clin Cancer Res; 2016 Dec; 22(24):6110-6117. PubMed ID: 27334838
[TBL] [Abstract][Full Text] [Related]
3. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Park JH; Inoue H; Kato T; Zewde M; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y
Cancer Sci; 2017 Mar; 108(3):488-496. PubMed ID: 28075524
[TBL] [Abstract][Full Text] [Related]
4. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
5. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Alhawas L; Amin KS; Salla B; Banerjee PP
Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
[TBL] [Abstract][Full Text] [Related]
6. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
7. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Lunghi P; Giuliani N; Mazzera L; Lombardi G; Ricca M; Corradi A; Cantoni AM; Salvatore L; Riccioni R; Costanzo A; Testa U; Levrero M; Rizzoli V; Bonati A
Blood; 2008 Sep; 112(6):2450-62. PubMed ID: 18583568
[TBL] [Abstract][Full Text] [Related]
8. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis.
Gao T; Hu Q; Hu X; Lei Q; Feng Z; Yu X; Peng C; Song X; He H; Xu Y; Zuo W; Zeng J; Liu Z; Yu L
Cancer Lett; 2019 Mar; 445():11-23. PubMed ID: 30590102
[TBL] [Abstract][Full Text] [Related]
9. PDZ-binding kinase inhibitor OTS514 suppresses the proliferation of oral squamous carcinoma cells.
Kato M; Ota A; Ono T; Karnan S; Hyodo T; Rahman ML; Hasan MN; Onda M; Kondo S; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
Oral Dis; 2024 Mar; 30(2):223-234. PubMed ID: 36799330
[TBL] [Abstract][Full Text] [Related]
10. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Herbert KJ; Ashton TM; Prevo R; Pirovano G; Higgins GS
Cell Death Dis; 2018 Oct; 9(11):1089. PubMed ID: 30356039
[TBL] [Abstract][Full Text] [Related]
11. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
[TBL] [Abstract][Full Text] [Related]
12. TOPK inhibition accelerates oxidative stress‑induced granulosa cell apoptosis via the p53/SIRT1 axis.
Park JH; Park SA; Lee YJ; Joo NR; Shin J; Oh SM
Int J Mol Med; 2020 Nov; 46(5):1923-1937. PubMed ID: 32901866
[TBL] [Abstract][Full Text] [Related]
13. [
Pirovano G; Roberts S; Brand C; Donabedian PL; Mason C; de Souza PD; Higgins GS; Reiner T
Mol Imaging Biol; 2019 Aug; 21(4):705-712. PubMed ID: 30357568
[TBL] [Abstract][Full Text] [Related]
14. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
15. TOPK Activation Exerts Protective Effects on Cisplatin-induced Acute Kidney Injury.
Zhang H; Dong QQ; Shu HP; Tu YC; Liao QQ; Yao LJ
Curr Med Sci; 2022 Aug; 42(4):742-753. PubMed ID: 35678915
[TBL] [Abstract][Full Text] [Related]
16. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase.
Diao X; Yang D; Chen Y; Liu W
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980
[TBL] [Abstract][Full Text] [Related]
17. Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress.
Herbert KJ; Puliyadi R; Prevo R; Rodriguez-Berriguete G; Ryan A; Ramadan K; Higgins GS
Cell Death Differ; 2021 Apr; 28(4):1333-1346. PubMed ID: 33168956
[TBL] [Abstract][Full Text] [Related]
18. TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
Pirovano G; Ashton TM; Herbert KJ; Bryant RJ; Verrill CL; Cerundolo L; Buffa FM; Prevo R; Harrap I; Ryan AJ; Macaulay V; McKenna WG; Higgins GS
Br J Cancer; 2017 Aug; 117(4):503-512. PubMed ID: 28677687
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
20. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.
Matsuo Y; Park JH; Miyamoto T; Yamamoto S; Hisada S; Alachkar H; Nakamura Y
Sci Transl Med; 2014 Oct; 6(259):259ra145. PubMed ID: 25338756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]